ArticleESMO gastrointestinal oncology2026
Baseline and dynamic cytokines as biomarkers for immune checkpoint and anti-VEGF therapy in advanced hepatocellular carcinoma.
Article in ESMO gastrointestinal oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immune checkpoint inhibitors (ICIs), or the combination of ICIs and vascular endothelial growth factor (VEGF) inhibitors, are the preferred treatments for advanced hepatocellular carcinoma (HCC). However, the immunomodulatory effects of anti-VEGF therapy in HCC remain poorly understood. Predictive biomarkers are needed to guide therapy selection. Patients and methods: We prospectively analyzed circulating cytokines in patients with advanced HCC receiving ICIs with or without anti-VEGF inhibitor therapy as standard of care. Serum samples were collected at baseline and ∼2 months after treatment initiation. A 32-cytokine Luminex panel was used to assess systemic immune changes. We examined associations between treatment group, cytokine dynamics, and clinical outcomes. Results: Among 56 enrolled patients, 35 patients were treated with ICIs only (ICI-only), and 21 patients were treated with ICIs plus the VEGF inhibitor bevacizumab (ICI + Bev). Demographic characteristics and treatment outcomes were generally balanced between the two groups. As compared with ICI-only, patients receiving ICI + Bev exhibited significantly reduced fold changes in multiple cytokines on treatment, including sCD40L, macrophage inflammatory protein-1β (MIP-1β), monokine induced by interferon-γ (MIG), and interleukin (IL)-1Ra, of which above-median circulating baseline levels of MIP-1β were associated with inferior clinical outcomes. In addition, patients with above-median circulating levels of IL-6 and IL-12p40 at baseline had longer progression-free survival with ICI + Bev versus ICI-only. Treatment-associated reductions in IL-1Ra, IL-8, IL-18, and VEGF-A were associated with favorable clinical outcomes. Conclusions: In a highly exploratory analysis, myeloid-inflammatory signatures at baseline and treatment-associated reductions in key myeloid cytokines may identify patients most likely to benefit from adding Bev to ICI. Prospective validation of these markers in independent cohorts is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.